Antiemetic effect and safety of concurrent administration of
ondansetron and other
antiemetics (
dexamethasone,
domperidone and
ethyl loflazepate), given for complete suppression of
nausea/
vomiting, were examined in 46 patients (109 courses) with gynecological
cancer receiving single high-dose of
cisplatin or
carboplatin. As for the delayed
emesis,
antiemetic effect depending on the
steroid treatment duration, given concurrently to
ondansetron, was compared. The results were as follows; 1. In 78 courses, anticancer drugs were given concurrently to
cisplatin or
carboplatin only on Day 1. In the remaining 31 courses, those drugs were concurrently administered up to Day 6 at the longest. 2. Complete suppression (i.e., no onsets) rate of acute
emesis was 64.2% (70/109 courses) for
nausea, and 84.4% (92/109 courses) for
vomiting. 3. When the complete suppression depending on duration of concomitant
steroid was examined mainly in patients receiving CAP (
cyclophosphamide,
adriamycin and
cisplatin), higher
antiemetic effect, especially in
nausea, was observed in those on concomitant
steroids for 3 days compared to that for 1 day. 4. The food intake rate improved along with
nausea symptoms. 5. No adverse event or laboratory abnormality due to the multi-
antiemetic treatment was observed. Based on the above, the efficacy of the
antiemetic treatment in this study was confirmed. In delayed
emesis, concurrent
steroids given for 3 days after
chemotherapy were considered effective and were also regarded to improve food intake.